Single Agent Chemotherapy Market - By Drug Class , By Cancer , By Route of Administration, By End User and By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2024-2030

Report Code: HCR 1012 Report Format: PDF + Excel

Single Agent Chemotherapy Market Overview: 

Single Agent Chemotherapy Market size is estimated to reach $8.2 billion by 2030, growing at a CAGR of 3.9% during the forecast period 2024-2030. The increasing prevalence of cancer globally is a major driver of the market, as the rising number of cancer cases necessitates effective treatment options. Government investment in healthcare infrastructure, advances in drug development and the approval of new single agent chemotherapeutic drugs are further propelling market growth.

Innovations in drug delivery systems, such as targeted delivery mechanisms and nanotechnology, are expected to enhance the precision and effectiveness of chemotherapy treatments. The market is also witnessing a shift towards personalized medicine, where treatment regimens are tailored to the genetic profile of individual patients, thereby improving outcomes and minimizing adverse effects. Furthermore, the integration of artificial intelligence and machine learning in drug discovery and development processes is anticipated to accelerate the creation of new and more effective chemotherapeutic agents.

Single Agent Chemotherapy Market - Report Coverage:

The “Single Agent Chemotherapy Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Single Agent Chemotherapy Market.

Attribute Segment

By Drug Class
  • Alkylating Agents
  • Antimetabolites
  • Anti-tumor Antibiotics
  • Topoisomerase Inhibitors
  • Mitotic Inhibitors
  • Others

By Cancer
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Leukemia
  • Lymphoma
  • Other

By Route of Administration
  • Intravenous (IV)
  •  Oral
  • Subcutaneous (SC)
  • Intramuscular (IM)

By End User
  • Hospitals & Clinics
  • Specialty Centers
  • Others

By Geography

·       North America (U.S, Canada and Mexico)

·       Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

·       Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

·       South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

·       Rest of the World (Middle East and Africa).

Key Takeaways:
•    Dominance of North America

Geographically, North America held the largest share with 35% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. North America, particularly the United States, faces a significant burden of cancer. An aging population and unhealthy lifestyle choices are contributing factors. The American Cancer Society released its Cancer Statistics 2023 report, which showed that in 2023 in the United States, there will be nearly 2 million new cases of cancer diagnosed. This translates to a larger pool of patients requiring cancer treatment, including single agent chemotherapy. 

•    Breast Cancer is the largest Segment

In terms of cancer, breast cancer is the largest segment in 2023 due to its high prevalence and significant mortality rate, making it a primary focus for treatment advancements. The disease affects a large female population globally, with increasing incidence rates driven by factors such as lifestyle changes, genetic predispositions and longer life expectancies. According to the American Cancer Society, breast cancer is the most common cancer diagnosed among women in the United States. It is the 2nd leading cause of death from cancer among women. Single agent chemotherapy is often utilized in breast cancer treatment due to its efficacy in specific stages and types of breast cancer, providing a less complex and targeted approach compared to combination therapies.

•    Improved Healthcare Infrastructure to Drive the Market

Government initiatives and investments are improving healthcare infrastructure globally. In July 2024, the Australian government invested approximately $720 million into developing the 150-bed Queensland Cancer Centre which is slated to open in 2028. Its establishment aligns with the government’s Queensland Cancer Plan, a 10-year initiative with over $1.1 billion in investments. In September 2023, the Kerala Infrastructure Investment Fund Board (KIIFB) allotted approximately $24 million towards ensuring the full-fledged operations of Cochin Cancer Research Centre (CCRC). Such developments translate to better access to advanced cancer treatment facilities, including chemotherapy, thereby boosting the single agent chemotherapy market.

•    High Cost of Treatment to Impede Growth

Single Agent Chemotherapy drugs can be expensive, posing a significant financial burden on patients. As cancer survival rates rise, so do the price tags of life-saving treatments. Monthly drugs costs may reach $100,000, causing many Americans to struggle with the physical and emotional effects of high out-of-pocket medical costs. Even worse, others are completely priced out of the hope for a cure. $245 billion is expected to be spent on cancer care costs in the U.S. by 2030, as per the American Association for Cancer Research. Nearly 20% of cancer patients and their loved ones surveyed by The Mesothelioma Center at Asbestos.com estimated that they spent more than $20,000 each year in total out-of-pocket costs.


Market: Market Share (%) by Geography, 2023
 

For more details on this report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Single Agent Chemotherapy Market. The top 10 companies in the Single Agent Chemotherapy Market are:

  1. F. Hoffmann-La Roche AG
  2. Bristol Myers Squibb
  3. AbbVie
  4. Pfizer Inc.
  5. Janssen Biotech
  6.  GlaxoSmithKline
  7. Novartis AG
  8.  AstraZeneca
  9. Teva Pharmaceuticals Industries
  10. Sanofi S.A

For more Lifesciences and Healthcare related reports, please click here

 

  1.    Single Agent Chemotherapy Market- Market Overview
      1.1    Definitions and Scope 
  2.    Single Agent Chemotherapy Market - Executive Summary
      2.1    Key Trends by Drug Class
      2.2    Key Trends by Indication
      2.3    Key Trends by Route of Administration
      2.4    Key Trends by End Use Industry
      2.5    Key Trends by Geography
  3    Single Agent Chemotherapy Market – Comparative analysis 
      3.1    Market Share Analysis- Major Companies
      3.2    Product Benchmarking- Major Companies
      3.3    Top 5 Financials Analysis
      3.4    Patent Analysis- Major Companies
      3.5    Pricing Analysis (ASPs will be provided)
  4    Single Agent Chemotherapy Market - Startup companies Scenario Premium 
      4.1    Major startup company analysis:
            4.1.1    Investment
            4.1.2    Revenue
            4.1.3    Product portfolio
            4.1.4    Venture Capital and Funding Scenario
  5    Single Agent Chemotherapy Market – Industry Market Entry Scenario Premium 
      5.1    Regulatory Framework Overview
      5.2    New Business and Ease of Doing Business Index
      5.3    Successful Venture Profiles
      5.4    Customer Analysis – Major companies
  6    Single Agent Chemotherapy Market - Market Forces
      6.1    Market Drivers
      6.2    Market Constraints
      6.3    Porters Five Force Model
            6.3.1    Bargaining Power of Suppliers
            6.3.2    Bargaining Powers of Buyers
            6.3.3    Threat of New Entrants
            6.3.4    Competitive Rivalry
            6.3.5    Threat of Substitutes 
  7    Single Agent Chemotherapy Market – Strategic Analysis
      7.1    Value/Supply Chain Analysis
      7.2    Opportunity Analysis
      7.3    Product/Market Life Cycle
      7.4    Distributor Analysis – Major Companies 
  8    Single Agent Chemotherapy Market – By Drug Class (Market Size –$Million/$Billion)
      8.1    Alkylating Agents.
      8.2    Antimetabolites 
      8.3    Anti-Tumor Antibiotics
      8.4    Topoisomerase Inhibitors
      8.5    Mitotic Inhibitors 
      8.6    Others
  9    Single Agent Chemotherapy Market – By Cancer (Market Size –$Million/$Billion)
      9.1    Breast Cancer
      9.2     Lung Cancer
      9.3    Colorectal Cancer
      9.4    Leukemia
      9.5    Lymphoma
      9.6    Others
  10    Single Agent Chemotherapy Market – By Route of Administration (Market Size –$Million/$Billion)
      10.1    Intravenous (IV)
      10.2    Oral
      10.3    Subcutaneous (SC)
      10.4    Intramuscular (IM)
  11    Single Agent Chemotherapy Market – By Enduse (Market Size –$Million/$Billion)
      11.1    Hospitals & Clinics
      11.2    Specialty Centers
      11.3    Homecare Settings
  12    Single Agent Chemotherapy Market - By Geography (Market Size -$Million/Billion)
      2.1 North America
            2.1.1    USA
            2.1.2    Canada
            2.1.3    Mexico
      2.2 Europe
            2.2.1    UK
            2.2.2    Germany
            2.2.3    France
            2.2.4    Italy
            2.2.5    Netherlands
            2.2.6    Spain
            2.2.7    Belgium
            2.2.8    Rest of Europe
      2.3 Asia-Pacific
            2.3.1    China
            2.3.2    Japan
            2.3.3    India
            2.3.4    South Korea
            2.3.5    Australia
            2.3.6    Indonesia
            2.3.7    Thailand
            2.3.8    Malaysia
            2.3.9    Rest of APAC
      2.4 South America
            2.4.1    Brazil
            2.4.2    Argentina
            2.4.3    Colombia
            2.4.4    Chile
            2.4.5    Rest of South America
      2.5 Rest of the World
            2.5.1    Middle East
            2.5.2    Africa
  13    Single Agent Chemotherapy Market – Entropy
      13.1    New Product Launches
      13.2    M&As, Collaborations, JVs and Partnerships
  14    Single Agent Chemotherapy Market – Industry/Segment Competition Analysis
      14.1    Company Benchmarking Matrix – Major Companies
      14.2    Market Share at Global Level - Major companies
      14.3    Market Share by Key Region - Major companies
      14.4    Market Share by Key Country - Major companies
      14.5    Market Share by Key Application - Major companies
      14.6    Market Share by Key Product Type/Product category - Major companies
  15    Single Agent Chemotherapy Market – Key Company List by Country Premium
  16    Single Agent Chemotherapy Market Company Analysis - Business Overview, Product Portfolio, Financials, and Developments
      16.1    F. Hoffmann-La Roche AG
      16.2    Bristol Myers Squibb
      16.3    AbbVie
      16.4    Pfizer Inc.
      16.5    Janssen Biotech
      16.6    GlaxoSmithKline
      16.7    Novartis AG
      16.8    AstraZeneca
      16.9    Teva Pharmaceuticals Industries
      16.10    Sanofi S.A
  "*Financials would be provided on a best-effort basis for private companies*”
  Connect with our experts to get customized reports that best suit your requirements. Our 
  reports include global-level data, niche markets and competitive landscape.